Scientist, New Yorker, Weill Cornell Medical Center. Cancer Biologist, Lung and Breast cancer basic and translational research. Views are my own.
New York, New York
Joined November 2012
- Tweets1.2K
- Following303
- Followers624
- Likes1.3K
Vivek Mittal retweeted
The personalized neonantigen vaccines to treat cancer, already shown to work in malignant melanoma, and in trials of pancreatic cancer, glioblastoma, renal cell cancer, and triple-negative breast cancer.....now ovarian cancer. Results from a Phase 1 trial
nature.com/articles/s41591-0…
Timely. Amazing meeting happening right now in Italy. Copper 2026. copper2026.auburn.edu/prelim…
Glad to share our comment on @SpringerNature about a recent @CellCellPress paper on the #immunogenic potential of #cuproptosis for #cancer #therapy. @FoxChaseCancer @CRCordeliers @GustaveRoussy Available at rdcu.be/LMrWBso2Sp3a
Vivek Mittal retweeted
The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the most refractory cancers: pancreatic, melanoma, glioblastoma, renal, triple-negative breast cancer.
✓ out the new Ground Truths (link in profile)
🤖 Made with AI
Vivek Mittal retweeted
People often ask how breakthroughs occur in cancer biology-often the story is more complex - the survival plot for myeloma outcomes is extraordinary - improvements come about in incremental steps - in my lifetime treatment of Myeloma has almost transformed into a curable disease
Vivek Mittal retweeted
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche
nature.com/articles/s43018-0…
Vivek Mittal retweeted
Final call to register for the March 30 CAP-IT Summit!
forms.gle/19GKAY6ADTXsjoqy5
Don’t miss the opportunity to engage with leaders in cancer prevention and interception.
Vivek Mittal retweeted
The three CAP-IT U54 centers presented updates on their research progress. Drs. Vivek Mittal @mittallab and Julie Magarian Blander of @WeillCornell highlighted efforts from the CAP-IT Center for LNP nucleic acid cancer immunoprevention.
Vivek Mittal retweeted
@WCM is studying new treatments for non-small cell lung cancer (IB–III N2).
Compare chemo + immunotherapy vs radiation + immunotherapy.
✅ Age 18+, potentially resectable disease.
📞 [email protected] | 212-746-5156
IRB #24-02027124
Learn more & see if you qualify!
Vivek Mittal retweeted
At today’s #CAPITSCMeeting, we were honored to be joined by two patient advocates: Ms. Robin Beth Dubin from @Alive_And_Kickn and Ms. Erica Kirschner from @LFSAssociation. Their powerful stories and perspectives deeply moved us and reinforced the importance of CAP-IT’s mission to discover molecularly and immunologically targeted agents to prevent or intercept cancer in high-risk populations.
Dr. Margie Clapper of @FoxChaseCancer, Chair of the Resource Sharing Working Group, shared updates on WG activities, including development of a searchable shared resource catalog with technical assistance from the CAP-IT DRCC team at @RoswellPark.
Dr. Yongfeng He @YongfengHe_PhD from @mittallab of @WeillCornell U54 presented updates on their LNP mRNA vaccine project aimed at intercepting the progression from pre-invasive to invasive lung cancer, sparking strong interest and discussion.
Vivek Mittal retweeted
The Role of PD-1 in Maintaining Stem-like CD8+ T Cells @Nature
✅PD-1 doesn’t just “brake” — it fine-tunes TCR signaling to prevent exhaustion of precious stem-like CD8+ T cells
✅Blocking PD-1 can depletes these stem-like progenitors
👉PD-1 might be less an off-switch and more a quality controller for long-term T cell immunity
nature.com/articles/s41586-0…
@OncoAlert
Vivek Mittal retweeted
What if a cancer-causing mutation were less like a ticking time bomb and more like an actor waiting for the right opportunity? Team SPECIFICANCER’s brand new paper gives us an insight.
The new paper from SPECIFICANCER, published in @Nature, reveals that it’s not just the mutation that matters — it’s where in the liver that mutation appears. Understanding which cells can turn cancerous — and why — helps us better predict risk and develop smarter, more targeted treatments.
Congratulations to the #CancerGrandChallenges SPECIFICANCER team (co-funded by @TheMarkFdn). This work was led by Owen Sansom and Future Leader Alex Raven.
👉 Read more from Alex: lnkd.in/eTVh9YY6
#CancerResearch
So gratifying to see state-of-the art cancer research laboratory dedicated to discovering next generation cancer vaccines @CrestTcg . As a founding member and scientific advisor it’s exciting to see this vision come to life shorturl.at/POhmD. shorter.at/HFrtw
Our paper "Epigenetic regulation of CIN in TNBC" is out in Cancer Discovery shorturl.at/EcEfW Fantastic collaboration with @Samuel_Bakhoum @Dow_lab @LabMelnick @LaughneyLab @ElementoLab
@WeillCornell @BCRFcure @AmericanCancerS @TNBCFoundation #Chromosomal_Instability
The translational part: EZH2 inhibitors like tazemetostat are already FDA-approved for other cancers. Repurposing them for TNBC could provide a rapid path to new anti-metastatic therapies.